Akebia Therapeutics Inc (AKBA) (Q3 2026) Earnings Call Highlights: Vafseo Demand Outpaces ...
Akebia Therapeutics Inc (AKBA) sees strong underlying Vafseo demand and positive VOICE/VOCAL data offsetting Auryxia generic pressure and a swing to a Q3 net loss. Related Stocks: AKBA ,